Jeffrey Bertolini, Chief Operating Officer of Carlsmed, Inc. (NASDAQ:CARL), filed a Form 4 on November 4, 2026, disclosing a stock option exercise and same-day sale of 747 shares of common stock on November 3, 2026.

Key Highlights

  • Option exercise: Bertolini exercised a stock option for 747 shares of common stock at an exercise price of $5.915 per share on November 3, 2026.
  • Shares sold: 747 shares of common stock were disposed of at $15.15 per share on November 3, 2026.
  • 10b5-1 plan: According to the filing, the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Bertolini on March 12, 2026.
  • Remaining beneficial ownership: Following the transactions, Bertolini directly held 22,489 shares of common stock.
  • Remaining options: Bertolini retained 20,908 derivative securities (stock options with a right to buy common stock) with an exercise price of $5.915 and an expiration date of April 9, 2035.
  • Vesting schedule: The filing states that 25% of the original option shares vested on March 3, 2026, with the remaining 75% vesting in 1/36th installments on a monthly basis thereafter, subject to continued service.

Bertolini's November 3 Option Exercise and Share Sale at Carlsmed

According to the Form 4 filed with the SEC, Jeffrey Bertolini, the Chief Operating Officer of Carlsmed, Inc. (NASDAQ:CARL), reported two transactions in common stock on November 3, 2026. First, Bertolini exercised a stock option (transaction code "M") covering 747 shares at an exercise price of $5.915 per share, bringing his directly held common stock position to 23,236 shares following that acquisition.

Immediately following the exercise, Bertolini disposed of 747 shares (transaction code "S") at a price of $15.15 per share. The filing notes that these sales were carried out under a Rule 10b5-1 trading plan that Bertolini adopted on March 12, 2026. After both transactions, his direct beneficial ownership of common stock stood at 22,489 shares.

In Table II of the filing, the underlying stock option from which the 747 shares were drawn is described as having a conversion/exercise price of $5.915 and an expiration date of April 9, 2035. The filing discloses that 25% of the original number of option shares vested on March 3, 2026, with the remaining 75% vesting in 1/36th monthly installments thereafter, contingent on Bertolini's continued service. Following the exercise of 747 shares, Bertolini's remaining stock option position was reported as 20,908 derivative securities. The Form 4 was signed by Michael Cordonnier as attorney-in-fact for Jeffrey Bertolini and filed on November 4, 2026.

What Was Disclosed

Carlsmed, Inc. COO Jeffrey Bertolini reported the exercise of 747 stock options at $5.915 per share and the sale of 747 common shares at $15.15 per share on November 3, 2026, under a pre-established Rule 10b5-1 trading plan, leaving him with 22,489 shares directly held.